CERVOMED ANNOUNCES INITIAL RESULTS FROM THE PHASE 2A CLINICAL TRIAL OF NEFLAMAPIMOD IN NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) HAVE BEEN ACCEPTED AS A LATE-BREAKING ORAL SESSION AT ISFTD 2026

Reuters · 1d ago

Please log in to view news